6 July 2020 - Mylan will launch a generic version of Gilead Sciences’ COVID-19 anti-viral remdesivir in India at 4,800 rupees, about 80% below the price tag on the drug for wealthy nations.
California-based Gilead has signed licensing deals with several generic drugmakers in an effort to make remdesivir available in 127 developing countries.
Last month, two Indian drugmakers, Cipla and privately-held Hetero Labs, also launched generic versions of the treatment. Cipla will price its version, Cipremi, at less than 5,000 rupees, while Hetero has priced Covifor at 5,400 rupees.